ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$8.12
0.23 (2.92%)
▲
5d:
-8.04%
30d:
+0.25%
90d:
-6.34%
HOLD
LOW Confidence
Analysis Updated: Jul 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
15d
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACET shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACET shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $8.12, which is considered slightly low relative to its 30-day fair value range of $8.03 to $8.82.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.76, while resistance sits at $9.31.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+329.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.76, while resistance sits at $9.31.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+329.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$8.03 -
$8.82
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 329.0% below Wall St target ($34.83)
- CAUTION: Recommendation downgraded due to -8.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$8.03 -
$8.82
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.03
(12.7%)
Support & Resistance Levels
Support Level
$7.76
Resistance Level
$9.32
Current Trend
Uptrend
Technical data as of
Jul 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.94
Wall Street Target
$34.83
(+329.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 21, 2026 5:48 PM ET
Data refreshes hourly during market hours. Next update: 6:48 PM
Data refreshes hourly during market hours. Next update: 6:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
74751 shares
2026-02-20
Ra Capital Management, L…
BUY
74268 shares
2026-02-19
Ra Capital Management, L…
BUY
74577 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 55 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 58 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 56 HOLD |
